Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2018-08-09 Major Shareholding Noti…
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2018
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "Major Shareholder Announcement" and details a change in the indirect ownership stake of BlackRock, Inc. in Genmab A/S, falling below a specific threshold (4.94%). This directly corresponds to the definition of a Major Shareholding Notification. The document length is relatively short (4570 chars), but the content is the primary announcement itself, not just a notice that a report is attached, making 'MRQ' (Major Shareholding Notification) the most accurate classification over 'RPA' or 'RNS'.
2018-08-09 English
Major Shareholder Announcement
Major Shareholding Notification Classification · 100% confidence The document is titled 'Major Shareholder Announcement' and explicitly states that BlackRock, Inc. has decreased its ownership in Genmab A/S, crossing a reporting threshold. This aligns perfectly with the definition of a Major Shareholder Notification (MRQ).
2018-08-09 English
Report Publication Announcement 2018
Report Publication Announcement Classification · 95% confidence The document is a press release announcing the financial results for the first half of 2018. While it contains summary financial data, it explicitly refers to an attached 'Interim Report' and provides a link to download the full report. According to the 'Menu vs Meal' rule, a document that announces the publication of a report and provides a link to it, rather than being the full report itself, is classified as a Report Publication Announcement (RPA). H1 2018
2018-08-08 English
Genmab Announces Financial Results for the First Half of 2018
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report for the First Half of 2018' and contains comprehensive financial statements, including consolidated key figures, income statements, balance sheets, cash flow statements, and notes to the financial statements. It is a 38-page document (as indicated by the page numbering) that provides a detailed financial review and outlook, fitting the definition of an Interim/Quarterly Report (IR). It is not merely an announcement of a report, as it contains the full financial data. H1 2018
2018-08-08 English
Legal Proceedings Report 2018
Legal Proceedings Report Classification · 99% confidence The document is explicitly titled 'Company Announcement' and details a positive opinion from the CHMP regarding a drug (DARZALEX). It is a brief press release format, not a comprehensive financial report (like 10-K or IR). It announces a regulatory/clinical milestone. Since it is a general announcement that doesn't fit the specific categories like ER, DIV, or CAP, and it is not a full transcript (CT) or a formal legal filing, it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous corporate announcement regarding regulatory progress, or potentially a specialized announcement if one existed. Given the options, RNS serves as the best general regulatory announcement fallback for non-financial/non-governance specific news. However, since it is a specific announcement about a regulatory step (CHMP opinion), and not a general filing, I will check if any other category fits better. It is not a Director's Dealing (DIRS), Capital Change (CAP), or Earnings Release (ER). It is a specific announcement about a drug approval process milestone. In the absence of a specific 'Regulatory Milestone Announcement' code, RNS (Regulatory Filings) is the most appropriate general category for this type of news release.
2018-07-27 English
CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Front Line Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab regarding a positive regulatory opinion (CHMP) for a drug (DARZALEX). It provides details on the clinical study (ALCYONE), the regulatory process, and background on the company's pipeline. It does not fit into specific financial reporting categories like 10-K or IR, nor is it a simple report publication notice (RPA). As it is a general regulatory/corporate announcement regarding product development and regulatory status, it falls under the RNS (Regulatory Filings) category.
2018-07-27 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.